Left Ventricular Hypertrophy: Etiology-Based Therapeutic Options
Open Access
- 30 March 2022
- journal article
- review article
- Published by Springer Nature in Cardiology and Therapy
- Vol. 11 (2) , 203-230
Abstract
Determining the etiologies of left ventricular hypertrophy (LVH) can be challenging due to the similarities of the different manifestations in clinical presentation and morphological features. Depending on the underlying cause, not only left ventricular mass but also left ventricular cavity size, or both, may increase. Patients with LVH remain asymptomatic for a few years, but disease progression will lead to the development of systolic or diastolic dysfunction and end-stage heart failure. As hypertrophied cardiac muscle disrupts normal conduction, LVH predisposes to arrhythmias. Distinguishing individuals with treatable causes of LVH is important for prevention of cardiovascular events and mortality. Athletic’s heart with physiological LVH does not require treatment. Frequent causes of hypertrophy include etiologies due to pressure/volume overload, such as systemic hypertension, hypertrophic cardiomyopathy, or infiltrative cardiac processes such as amyloidosis, Fabry disease, and sarcoidosis. Hypertension and aortic valve stenosis are the most common causes of LVH. Management of LVH involves lifestyle changes, medications, surgery, and implantable devices. In this review we systematically summarize treatments for the different patterns of cardiac hypertrophy and their impacts on outcomes while informing clinicians on advances in the treatment of LVH due to Fabry disease, cardiac amyloidosis, and hypertrophic cardiomyopathy.Keywords
This publication has 150 references indexed in Scilit:
- Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic reviewHeart, 2013
- Long‐term outcome of enzyme‐replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complicationsJournal of Internal Medicine, 2013
- New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival OutcomesJournal of Clinical Oncology, 2012
- Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosisEuropean Heart Journal, 2012
- Dofetilide Reduces the Frequency of Ventricular Arrhythmias and Implantable Cardioverter Defibrillator TherapiesJournal of Cardiovascular Electrophysiology, 2011
- Research Priorities in Hypertrophic CardiomyopathyCirculation, 2010
- Fabry diseaseOrphanet Journal of Rare Diseases, 2010
- Regression of Left Ventricular Mass by Antihypertensive TreatmentHypertension, 2009
- Pathological versus physiological left ventricular hypertrophy: A reviewJournal of Sports Sciences, 1998
- Non-invasive assessment of diastolic function in hypertrophic cardiomyopathy on and off beta adrenergic blocking drugs.Heart, 1982